Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593944 · ClinicalTrials.gov registry record · Phase 1
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00593944 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants.
The verdict
NCT00593944, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL). Information on any responses that patients may have to the drug will also be collected.
Interventions
- BIOLOGICAL MDX-1342
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593944
The ClinicalTrials.gov registry entry for NCT00593944 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-1342 is the first listed.
NCT00593944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593944 about?
NCT00593944 is a clinical study titled "Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL). Information on any responses that patients may have to the drug will also be collected.
What is the current status of trial NCT00593944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00593944?
The interventions under investigation include: MDX-1342 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00593944?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.